Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J. Sanyal, Jörn M. Schattenberg, Philip N. Newsome
Topics & Concepts
SteatohepatitisSemaglutidePlaceboCirrhosisMedicineInternal medicineSteatosisFatty liverGastroenterologyLiraglutideEndocrinologyDiabetes mellitusAlternative medicineType 2 diabetesDiseasePathologyLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationDiabetes Treatment and Management